4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood t cells against b-cell malignancies

Human Gene Therapy

Volumn 21, Issue 1, 2010, Pages 75-86

  Tammana, Syam ^a   Huang, Xin ^a,c   Wong, Marianna ^a,c   Milone, Michael C ^d,e   Ma, Linan ^b   Levine, Bruce L ^d,e   June, Carl H ^d,e   Wagner, John E ^a,b   Blazar, Bruce R ^a,c   Zhou, Xianzheng ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CD137 ANTIGEN; CD19 ANTIBODY; CD28 ANTIGEN; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 2; LENTIVIRUS VECTOR; LYMPHOCYTE ANTIGEN RECEPTOR; OKT 3; UCB1 1928BBZETA; UCB1 19BBZETA; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER GENE THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; FEMALE; IMMUNOPHENOTYPING; LEUKEMIA CELL; LYMPHOMA CELL; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR; UMBILICAL CORD BLOOD;

ANIMALS; ANTIGENS, CD137; ANTIGENS, CD19; ANTIGENS, CD28; B-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FETAL BLOOD; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOPHENOTYPING; INTERFERON-GAMMA; INTERLEUKIN-2; LENTIVIRUS; LEUKEMIA; LYMPHOMA; MICE; MICE, SCID; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

MUS;

EID: 74949124101     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.122     Document Type: Article

References (43)

1. Altvater, B., Pscherer, S., Landmeier, S., Niggemeier, V., Juergens, H., Vormoor, J., and Rossig, C. (2006). CD28 co-stimulation via tumor-specific chimeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells. Clin. Exp. Immunol. 144, 447-457.
2. Amendola, M., Venneri, M.A., Biffi, A., Vigna, E., and Naldini, L. (2005). Coordinate dual-gene transgensis by lentiviral vectors carrying synthetic bidirectional promoters. Nat. Bio-technol. 23, 108-116.
3. Barker, J.N., and Wagner, J.E. (2003). Umbilical-cord blood transplantation for the treatment of cancer. Nat. Rev. Cancer 3, 526-532.
4. Brentjens, R.J., Latouche, J.B., Santos, E., Marti, F., Gong, M.C., Lyddane, C., King, P.D., Larson, S., Weiss, M., Rivière, I., and Sadelain, M. (2003). Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukein-15. Nat. Med. 9, 279-286.
5. Brentjens, R.J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., Quintàs-Cardama, A., Larson, S.M., and Sadelain, M. (2007). Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13, 5426-5435.
6. Carpenito, C., Milone, M.C., Hassan, R., Simonet, J.C., Lakhal, M., Suhoski, M.M., Varela-Rohena, A., Haines, K.M., Heitjan, D.F., Albelda, S.M., Carrol, R.G., Riley, J.L., Pastna, I., and June, C.H. (2009). Control of large, established tumor xeno-grafts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. U. S. A. 3, 3360-3365.
7. Chao, N., Emerson, S.G., and Weinberg, K.I. (2004). Stem cell transplantation (cord blood transplants). Hematol. Am. Soc. Hematol. Educ. Program 2004, 354-363.
8. Cooper, L.J.N., Topp, M.S., Serrano, L.M., Gonzalez, S., Chang, W.C., Naranjo, A., Wright, C., Popplewell, L., Raubitschek, A., Forman, S.J., and Jensen, M.C. (2003). T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101, 1637-1644.
9. Eshhar, Z., Waks, T., Gross, G., and Schindler, D.G. (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immuno-globulin and T-cell receptors. Proc. Natl. Acad. Sci. U. S. A. 90, 720-724.
10. Finney, H.M., Akbar, A.N., and Lawson, A.D. (2004). Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J. Immunol. 172, 104-113.
11. Finney, H.M., Lawson, A.D.G., Bebbington, C.R., and Weir, A.N.C. (1998). Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161, 2791-2797.
12. Friedmann-Morvinski, D., Bendavid, A., Waks, T., Schindler, D., and Eshhar, Z. (2005). Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 105, 3087-3093.
13. Golovina, T.N., Mikheeva, T., Suhoski, M.M., Aqui, N.A., Tai, V.C., Shan, X., Liu, R., Balcarcel, R.R., Fisher, N., Levine, B.L., Carroll, R.G., Warner, N., Blazar, B.R., June, C.H., and Riley, J.L. (2008). CD28 costimulation is essential for human T regulatory expansion and function. J. Immunol. 181, 2855-2868.
14. Greenberg, P.D., and Riddell, S.R. (1999). Deficient cellular immunity-finding and fixing the defects. Science 285, 546-551.
15. Hassan, J., and Reen, D.J. (1997). Cord blood CD4\+ CD45RA\+ T cells achieve a lower magnitude of activation when compared with their adult counterparts. Immunology 90, 397-401.
16. Haynes, N.M., Trapani, J.A., Teng, M.W., Jackson, J.T., Cerruti, L., Jane, S.M., Kershaw, M.H., Smyth., M.J., and Darcy, P.K. (2002a). Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J. Immunol. 169, 5780-5786.
17. Haynes, N.M., Trapani, J.A., Teng, M.W., Jackson, J.T., Cerruti, L., Jane, S.M., Kershaw, M.H., Smyth, M.J., and Darcy, P.K. (2002b). Single-chain antigen recognition receptors that costi-mulate potent rejection of established experimental tumors. Blood 100, 3155-3163.
18. Hippen, K.L., Harker-Murray, P., Porter, S.B., Merkel, S.B., Londer, A., Taylor, D.K., Bina, M., Panoskaltsis-Mortari, A., Rubinstein, P., Van Rooijen, N., Golovina, T.N., Suhoski, M.M., Miller, J.S., Wagner, J.E., June, C.H., Riley, J.L., and Blazar, B.R. (2008). Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 112, 2847-2857.
19. Huang, X., Guo, H., Kang, J., Choi, S., Zhou, T.C., Tammana, S., Lees, C.J., Li, Z.Z., Milone, M., Levine, B.L., Tolar, J., June, C.H., McIvor, S., Wagner, J.E., Blazar, B.R., and Zhou, X. (2008). Sleeping beauty transposon-mediated engineering of human primary T cells for therapy of CD19\+ lymphoid malignancies. Mol. Ther. 16, 580-589.
20. Imai, C., Mihara, K., Andreansky, M., Nicholson, I.C., Pui, C.H., Geiger, T.L., and Campana, D. (2004). Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18, 676-684.
21. Kaminski, B.A., Kadereit, S., Miller, R.E., Keahy, P., Stein, K.R., Topa, D.A., Radivoyevitch, T., Veigl, M.L., and Laughlin, M.J. (2003). Reduced expression of NFAT-associated genes in UCB versus adult CD4\+ T lymphocytes during primary stimulation. Blood 102, 4608-4617.
22. Kim, Y.-J., Han, M.-K., and Broxmeyer, H.E. (2008). 4-1BB regulates NKG2D costimulation in human cord blood CD8\+ T cells. Blood 111, 1378-1386.
23. Kloosterboer, F.M., Van Luxemburg-Heijs, S.A., Willemze, R., and Falkenburg, J.H. (2006). Similar potential to become activated and proliferate but differential kinetics and profiles of cytokine production of umbilical cord blood T cells and adult blood naive and memory T cells. Hum. Immunol. 67, 874-883.
24. Kowolik, C.M., Topp, M.S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D.D., Forman, S.J., Jensen, M.C., and Cooper, L.J. (2006). CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 66, 10995-11004.
25. Krause, A., Guo, H.F., Latouche, J.B., Tan, C., Cheung, N.K., and Sadelain, M. (1998). Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary lymphocytes. J. Exp. Med. 188, 619-626.
26. Loskog, A., Giandomenico, V., Rossig, C., Pule, M., Dotti, G., and Brenner, M.K. (2006). Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20, 1819-1828.
27. Maher, J., Brentjens, R.J., Gunset, G., Riviere, I., and Sadelain, M. (2002). Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRz=CD28 receptor. Nat. Bio-technol. 20, 70-75.
28. Marin, V., Kakuda, H., Dander, E., Imai, C., Campana, D., Biondi, A., and D'Amico, G. (2007). Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-z activating signal. Exp. Hematol. 35, 1388-1397.
29. Milone, M.C., Fish, J.D., Carpenito, C., Carroll, R.G., Binder, G.K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., Campana, D., Riley, J.L., Grupp, S.A., and June, C.H. (2009). Chimeric receptors containing CD137 signal trans-duction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453-1464.
30. Mirenda, V., Jarmin, S.J., David, R., Dyson, J., Scott, D., Gu, Y., Lechler, R.I., Okkenhaug, K., and Marelli-Berg, F.M. (2007). Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28. Blood 109, 2968-2977.
31. Nguyen, P., Moisini, I., and Geiger, T.L. (2003). Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function. Blood 102, 4320-4325.
32. Pule, M.A., Straathof, K.C., Dotti, G., Heslop, H.E., Rooney, C.M., and Brenner, M.K. (2005). A chimeric T cell antigen receptor that augments cytokine release and support clonal expansion of primary human T cells. Mol. Ther. 12, 933-941.
33. Riddell, S.R., and Greenberg, P.D. (1990). The use of anti-CD3 and anti-CD28 monoclonal antibodies to clones and expand human antigen-specific T cells. J. Immunol. Methods 128, 189-201.
34. Risdon, G., Gaddy, J., Horie, M., and Broxmeyer, H.E. (1995). Alloantigen priming induces a state of unresponsiveness in human umbilical cord blood T cells. Proc. Natl. Acad. Sci. U. S. A. 92, 2413-2417.
35. Rosenberg, S.A., Restifo, N.P., Yang, J.C., Morgan, R.A., and Dudley, M.K. (2008). Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8, 299-308.
36. Rossig, C., and Brenner, M. (2004). Genetic modification of T lymphcytes for adoptive immunotherapy. Mol. Ther. 10, 5-18.
37. Sadelain, M., Riviere, I., and Brentjens, R. (2003). Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3, 35-45.
38. Sallusto, F., and Lanzavecchia, A. (2004). Central memory and effector memory T cell subsets: Function, generation, and maintenance. Ann. Rev. Immunol. 22, 745-763.
39. Serrano, L.M., Pfeiffer, T., Olivares, S., Numbenjapon, T., Ben-nitt, J., Kim, D., Smith, D., McNamara, G., Al-Kadhimi, Z., Rosenthal, J., Forman, S.J., Jensen, M.C., and Cooper, L.J. (2006). Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for post transplantation adoptive immunotherapy. Blood 107, 2643-2652.
40. Wang, J., Jensen, M., Lin, Y., Sui, X., Chen, E., Lindgren, C.G., Till, B., Raubitschek, A., Forman, S.J., Qian, X., James, S., Greenberg, P., and Press, O.W. (2007). Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor processing CD28 and CD137 costim-ulatory domains. Hum. Gene Ther. 18, 712-725.
41. Watts, T.H. (2005). TNF=TNFR family members in costimulation of T cell responses. Ann. Rev. Immunol. 23, 23-68.
42. Weijtens, M.E., Hart, E.H., and Bolhuis, R.L. (2000). Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lym-phokine production. Gene Ther. 7, 35-42.
43. Zhang, H., Snyder, K.M., Suhoski, M.M., Maus, M.V., Kapoor, V., June, C.H., and Mackall, C.L. (2007). 4-1BB is superior to CD28 costimulation for generating CD8\+ cytotoxic lymphocytes for adoptive immunotherapy. J. Immunol. 179, 4910-4918.